Company news

AnGes. Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

AnGes.: Consolidated Financial Report for the Second Quarter 2026

August 14, 2026

Notice Regarding the Conduct of a Type B CMC Meeting for the HGF gene therapy product

May 14, 2026

Financial Results Summary of 1st Quarter 2026

May 8, 2026

AnGes.: Consolidated Financial Report for the First Quarter 2026

May 8, 2026

COLLATEGENE® (HGF gene therapy product); Proprietary ＆ USAN Names

April 29, 2026

Announcement of Publication of a Paper on Secondary Screening for Mucopolysaccharidoses Using Dried Blood Spots

April 2, 2026

Notice of First Patient Dosed in an Investigator-Initiated Clinical Trial Aimed at Preventing Brain Injury in Hemodialysis Patients Using the Jointly Developed Tie2 Receptor Agonist (AV-001)

March 24, 2026

Notice Regarding the Publication of the Research Article on Our HGF Gene Therapy Product in Circulation

March 10, 2026

Vasomune Therapeutics, Inc., and AnGes, Inc., Announce US FDA Clearance of Investigational New Drug (IND) Application For Pegevongitide (AV-001) Treatment in Resuscitation of Severely Burned Patients

March 4, 2026

Notice of the 27th annual general meeting of shareholders

March 2, 2026

Notice Regarding Partial Changes to the Use of Proceeds from the Issuance of the 46th Stock Acquisition Rights

February 24, 2026

Notice Regarding Execution of an Unsecured Private Placement Bond Facility (Revolving Type) Total Amount Purchase Agreement and Issuance of the 2nd Unsecured Corporate Bonds (Private Placement)

February 24, 2026

Introduction of the Policy Regarding Actions to Address Large-Scale Purchases of the Company’s Shares, etc. (Takeover Response Policy)

February 16, 2026

AnGes.: Consolidated Financial Report for the Fiscal Year 2025

February 10, 2026

Notice Regarding the Type “B” Clinical Meeting for HGF Gene Therapy Product

January 6, 2026

Notice of Joint Research Agreement on Zokinvy

December 9, 2025

Vasomune Therapeutics Inc., and AnGes Inc., Expand the Scope of the Co-Development Agreement to Target Additional Indications

November 25, 2025

AnGes.: Consolidated Financial Report for the Third Quarter 2025

November 7, 2025

Notice Regarding Revision of Consolidated Earnings Forecast for the Fiscal Year Ending December 2025

October 27, 2025

Notice of Expansion of License Agreement Scope by Our Subsidiary

September 4, 2025

Notice Regarding the Initiation of a New Clinical Study for the Jointly Developed Tie2 Receptor Agonist (AV-001)

September 3, 2025

ACRL Announcement on Commencement of Biomarker Testing for Mucopolysaccharidosis

August 26, 2025

HGF Gene Therapy Product: AnGes and Boehringer Enter Manufacturing Collaboration

August 20, 2025

AnGes.: Consolidated Financial Report for the Second Quarter 2025

August 8, 2025

Decks

The 5 newest of 26 decks. Every deck is listed under its year.